Embryonic stem cell trial back on

Nearly a year after the US Food and Drug Administration placed a hold on the first clinical trial of human embryonic stem cells, the company linkurl:Geron;http://www.geron.com/ has been cleared to continue its study of spinal cord injury, linkurl:it announced today;http://www.geron.com/media/pressview.aspx?id=1229 (July 30). Human embryonic stem cellsImage: Wikimedia commons, Nissim Benvenisty"We are pleased with the FDA's decision to allow our planned clinical trial of GRNOPC1 in spinal cord

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Nearly a year after the US Food and Drug Administration placed a hold on the first clinical trial of human embryonic stem cells, the company linkurl:Geron;http://www.geron.com/ has been cleared to continue its study of spinal cord injury, linkurl:it announced today;http://www.geron.com/media/pressview.aspx?id=1229 (July 30).
Human embryonic stem cells
Image: Wikimedia commons,
Nissim Benvenisty
"We are pleased with the FDA's decision to allow our planned clinical trial of GRNOPC1 in spinal cord injury to proceed," Geron's president and CEO Thomas Okarma said in a statement. The Phase I trial, which aims to use human ESC-derived progenitors of neural support tissue to treat patients with severe spinal cord injury, was to be the first-ever clinical trial of a hESC-based therapy when it was cleared by the FDA in January 2009. That August, however, before any patients had received treatment, the FDA linkurl:placed a hold;http://www.the-scientist.com/blog/display/55898/ on the trial after linkurl:cysts appeared;http://www.the-scientist.com/blog/display/55950/ in some of the animals given the treatment in a preclinical study. Since then, Geron completed an additional preclinical animal study to test new markers and assays, according to today's announcement. After submitting these results to the FDA, the hold was lifted, and the company has been cleared to begin administering the treatment to human patients. "Our goals for the application of GRNOPC1 in subacute spinal cord injury are unchanged," Okarma said -- "to achieve restoration of spinal cord function by the injection of hESC-derived oligodendrocyte progenitor cells directly into the lesion site of the patient's injured spinal cord."
**__Related stories:__***linkurl:Geron trial may resume next year;http://www.the-scientist.com/blog/display/56126/
[30th October 2009]*linkurl:Cysts stall stem cell trial?;http://www.the-scientist.com/blog/display/55950/
[27th August 2009]*linkurl:Human stem cell trial on hold;http://www.the-scientist.com/blog/display/55898/
[20th August 2009]*linkurl:FDA OKs stem cell trial;http://www.the-scientist.com/blog/display/55353/
[23rd January 2009]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Jef Akst

    Jef Akst was managing editor of The Scientist, where she started as an intern in 2009 after receiving a master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses.
Share
TS Digest January 2025
January 2025, Issue 1

Why Do Some People Get Drunk Faster Than Others?

Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.

View this Issue
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino
New Approaches for Decoding Cancer at the Single-Cell Level

New Approaches for Decoding Cancer at the Single-Cell Level

Biotium logo
Learn How 3D Cell Cultures Advance Tissue Regeneration

Organoids as a Tool for Tissue Regeneration Research 

Acro 

Products

Artificial Inc. Logo

Artificial Inc. proof-of-concept data demonstrates platform capabilities with NVIDIA’s BioNeMo

Sapient Logo

Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators

Bio-Rad Logo

Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization

Scientist holding a blood sample tube labeled Mycoplasma test in front of many other tubes containing patient samples

Accelerating Mycoplasma Testing for Targeted Therapy Development